SCHEMBL1908673

SCHEMBL1908673

Cc1cn2cc(S(=O)(=O)Cl)ccc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.41
KDM4E B2RXH2 7/20 0.38
GAA P10253 3/20 0.38
KMT2A Q03164 4/20 0.37
HPGD P15428 4/20 0.37
HSD17B10 Q99714 3/20 0.37
MEN1 O00255 3/20 0.37
HSP90AA1 P07900 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MCHR1 Q99705 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PTGS2 P35354 1/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
GFER P55789 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MITF O75030 1/20 0.35
KDM5A P29375 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25247062 0.81 ALDH1A1 (0.38) ALDH1A1KDM4EGAAKMT2AHPGD
SCHEMBL517211 0.78 SCN5A (0.49) ALDH1A1HSD17B10MCHR1TDP1PTGS2
SCHEMBL4790793 0.73 NPC1 (0.59) ALDH1A1KDM4EGAAKMT2AHPGD
SCHEMBL2242841 0.72 NPC1 (0.40) ALDH1A1KDM4EGAAKMT2AHPGD
SCHEMBL433724 0.72 RAB9A (0.56) ALDH1A1KDM4EKMT2AHPGDHSD17B10
SCHEMBL16825381 0.70 MEN1 (0.51) KMT2AMEN1
SCHEMBL1586 0.70 GAA (0.62) ALDH1A1KDM4EGAAKMT2AHPGD
SCHEMBL31231738 0.70 GAA (0.62) ALDH1A1KDM4EGAAKMT2AHPGD
SCHEMBL23653213 0.69 RAB9A (0.66) ALDH1A1GAAKMT2AHSD17B10MEN1
SCHEMBL7988504 0.68 APP (0.50) ALDH1A1KDM4EGAAKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9789118-B2 Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof NOVARTIS AG (CH) 2017-10-17 US disclosed
US-20140171363-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2014-06-19 US disclosed
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171363-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF ACACA, ACACB, COASY ALDH1A1 215/4885KDM4E 1416/4885GAA 339/4885
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF ACACA, ACACB, COASY ALDH1A1 215/4885KDM4E 1416/4885GAA 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.